Member Info for nofookinfear

No agenda sadoldgit just doing my own research as advised by most posters on here before deciding to stay or go.

Over its 22-year history since founding in 2003, Sareum Holdings has established itself as a lean, AIM-listed clinical-stage biotechnology company, though its operational progress is considered slow by industry standards. Operating with an ultra-light asset model (boasting just 5 core employees), its major milestones center around advancing a small portfolio of small molecule kinase inhibitors.Numerous modern biotech companies in the same sector have achieved significantly more, far more rapidly.Major Achievements of Sareum (2003–2025)Lead Asset Progression (SDC-1801): Successfully completed a Phase 1a/1b clinical trial for its dual TYK2/JAK1 inhibitor targeting autoimmune conditions like psoriasis. The trial demonstrated favorable safety and a once-daily oral dosing profile.Oncology Pipeline Assets: Advanced SDC-1802 through preclinical proof-of-concept stages for cancer immunotherapy. It also regained full commercial licensing control over SRA737 (a Chk1 inhibitor that previously completed Phase 2 trials under sub-licensees), securing 63.5% of all future revenues.Global IP & AI Alliances: Secured robust patent protections across major markets (US, Europe, China) for its lead assets. In 2025, it launched a strategic AI collaboration with Receptor.AI to design blood-brain barrier-permeable inhibitors.Financial Survival: Maintained a listed public presence on London's AIM marketplace (LON:SAR) primarily through periodic share subscriptions, keeping corporate overhead minimal.Industry Comparisons: Who Achieved More, More Quickly?While Sareum's lean methodology has kept it alive for over two decades, the broader biotech sector routinely sees companies launch, discover, scale, and bring assets to market (or multi-billion dollar exits) in less than half that timeframe.

According to AI folks which is apparently neutral to the bulls and the bears this is what your looking forward to x

AI the Verdict

Sareum is a textbook "binary" biotech play. If the mid-2026 toxicology data proves safe and successful, the stock could easily surge toward or past analyst targets as a Phase 2 asset becomes highly attractive for pharmaceutical licensing. However, any delays, formulation failures, or sudden emergency cash calls before year-end will likely tank the share.

Thank you for the kind compliment, I suppose it's better than being a knobhead!

Good point kasar, but don't be put off by speaking your mind by the likes of cater, its either positive here or go. Ask AI ;))

Place your bets folks the wheel is spinning 50/50 should I stay or should I go?

Whether Sareum Holdings PLC (LSE: SAR) will "make it" in the global pharmaceutical market remains highly speculative and represents a classic high-risk, high-reward biopharma scenario.As a clinical-stage biotechnology firm, Sareum does not yet sell commercial drugs or generate product revenue. Instead, its ultimate commercial success depends on successfully completing clinical trials and securing multi-million-dollar out-licensing or partnership deals with major pharmaceutical companies.🔬 Core Science: What Could Make Sareum Succeed?Sareum is developing next-generation small molecule kinase inhibitors targeting the TYK2/JAK1 pathway. This biological pathway is heavily involved in maintaining the human immune system.Lead Drug Candidate (SDC-1801): This oral, once-daily drug targets autoimmune diseases like plaque psoriasis. The TYK2 drug class was commercially validated by Bristol Myers Squibb’s blockbuster drug Sotyktu. Sareum's edge is its dual TYK2/JAK1 inhibition, which scientific models suggest could offer superior efficacy over drugs targeting just one enzyme.The Safety Advantage: Unlike older, less selective JAK inhibitors on the market, SDC-1801 is designed to spare the JAK2 and JAK3 pathways. This selective approach helps it avoid severe side effects like blood cell reductions or kidney function issues.Oncology and CNS Optionality: Beyond autoimmune treatments, Sareum holds promising early-stage cancer immunotherapies (SDC-1802), a cancer replication asset (SRA737), and a newer AI-driven collaboration targeting neuroinflammatory central nervous system diseases like Multiple Sclerosis.

Think someone may have sold a bit early!

Just doesn't make any since

That sell is actually my buy, not sure why they would mark otherwise!

Just dipped my toe in.

Much appreciated FunnyGuy. I might just dip my toe in again tomorrow.

Could they remove this from lse and then sell privately or would that need share holders approval?

And again wtf

255k sell

Spread has risen 3 times now 19.23% why?

Sorry 442.50p but you get the jest it will never ever see it again. But anyway hats off for dreaming!

Imoha the laws of average are stacked heavily against this ever reaching £44.25 ever again but 44.25p is very reachable.

Yesterday sorry not 3 days ago.

I have posted before but they were removed! I must of hit a nerve lol. There is no doubt in my mind that the share price will be lower next weekend due to Reality10 selling up. My last post 3 days ago was a follow up to his remark that you can't sell more the 1500 shares which my reply was i can buy £18400 for 22.9. Speaks volumes!